What is the translation of " OKVARJENIM DELOVANJEM JETER " in English?

• hepatic impairment
• impaired hepatic function
• impaired liver function
• liver impairment

Examples of using Okvarjenim delovanjem jeter in Slovenian and their translations into English

Bolniki z okvarjenim delovanjem jeter.
Patients with renal impairment.

Vendar ti simptomi niso vedno povezani z okvarjenim delovanjem jeter.
However, these symptoms are not always associated with abnormal liver function.

Bolniki z okvarjenim delovanjem jeter.
Patients with impairment of liver function.

Specifičnih farmakokinetičnih raziskav pri bolnikih z okvarjenim delovanjem jeter ni bilo.
No specific pharmacokinetic studies were carried out in patients with impaired liver function.

Bolniki z okvarjenim delovanjem jeter ali ledvic.
Patients with impaired hepatic or renal function.

Farmakokinetike kapsul HYCAMTIN niso posebej raziskali pri bolnikih z okvarjenim delovanjem jeter.
Pharmacokinetics of HYCAMTIN capsules have not been specifically studied in patients with impaired hepatic function.

Študij pri bolnikih z okvarjenim delovanjem jeter ali ledvic ni.
There are no studies in patients with impaired liver or kidney function.

Podatkov o dajanju odmerkov tadalafila, večjih od 10 mg, bolnikom z okvarjenim delovanjem jeter ni.
There are no available data about the administration of doses higher than 10 mg of tadalafil to patients with hepatic impairment.

Bolnikom z okvarjenim delovanjem jeter odmerkov ni treba prilagajati.
In patients with impaired liver function no dose adjustment is required.

Na voljo ni nobenih farmakokinetičnih podatkov za bolnike z okvarjenim delovanjem jeter ali starostnike(gt; 70 let).
There are no pharmacokinetic data available in patients with liver impairment or in the elderly(gt; 70 years).

Pri bolnikih z okvarjenim delovanjem jeter je očistek laktata lahko zmanjšan.
In patients with impaired liver function, lactate clearance may be restricted.

Okvara jeter Farmakokinetične lastnosti pri bolnikih z okvarjenim delovanjem jeter niso raziskane.
Hepatic impairment The pharmacokinetic properties have not been investigated in patients with impaired liver function.

Pri bolnikih s hudo okvarjenim delovanjem jeter je uporaba buprenorfina/naloksona kontraindicirana.
In patients with severe hepatic insufficiency the use of buprenorphine/naloxone is contraindicated.

O dajanju odmerkov tadalafila, višjih od 10 mg, bolnikom z okvarjenim delovanjem jeter ni podatkov.
There are no available data about the administration of doses higher than 10 mg of tadalafil to patients with hepatic impairment.

Študije pri bolnikih z okvarjenim delovanjem jeter ali ledvic niso bile opravljene.
Studies have not been carried out in patients with hepatic or renal impairment.

Z uporabo topotekana ni dovolj izkušenj pri bolnikih s hudo okvarjenim delovanjem jeter(bilirubin v serumu ≥ 10 mg/ dl).
There is insufficient experience of the use of topotecan in patients with severely impaired hepatic function(serum bilirubin≥ 10 mg/ dl).

Pri bolnikih z okvarjenim delovanjem jeter je očistek sirolimusa lahko zmanjšan(glejte poglavje 5.2).
The clearance of sirolimus may be reduced in patients with impaired hepatic function(see section 5.2).

Posebne skupine bolnikov Pri bolnikih z okvarjenim delovanjem jeter niso opravili farmakokinetičnih študij.
Special patient groups No pharmacokinetic studies have been performed in patients with impaired hepatic function.

Bolniki z okvarjenim delovanjem jeter Zdravila Glubrava pri bolnikih z okvarjenim delovanjem jeter ne smemo uporabljati(glejte poglavji 4. 3 in 4. 4).
Patients with hepatic impairment Glubrava should not be used in patients with hepatic impairment(see sections 4.3 and 4.4).

Ramucirumaba niso proučevali pri bolnikih s hudo okvarjenim delovanjem jeter(celokupni bilirubingt; 3,0 ULN in kakršna koli vrednost AST).
Ramucirumab has not been studied in patients with severe hepatic impairment(total bilirubingt; 3.0 ULN and any AST).

Bolniki z okvarjenim delovanjem jeter Pri bolnikih z okvarjenim delovanjem jeter odmerka zdravila BYETTA ni potrebno prilagajati(glejte poglavje 5. 2).
Patients with hepatic impairment No dosage adjustment of BYETTA is necessary in patients with hepatic impairment(see section 5.2).

Na voljo ni nobenih farmakokinetičnih podatkov za bolnike z okvarjenim delovanjem jeter, otroke ali mladostnike z Gaucherjevo boleznijo tipa 1 ali starostnike(gt; 70 let).
There are no pharmacokinetic data available in patients with liver impairment, in children or adolescents with type 1 Gaucher disease or in the elderly(gt; 70 years).

Pri bolnikih z blago okvarjenim delovanjem jeter(Child-Pugh razred A) niso opazili kakih pomembnih sprememb v farmakokinetiki.
In patients with mildly impaired liver function(Child-Pugh class A) no relevant changes in the pharmacokinetics have been observed.

Kombinacije CE/bazedoksifena pri bolnicah z okvarjenim delovanjem jeter(glejte poglavji 4.2 in 5.2) ali holestatskim ikterusom v anamnezi niso raziskovali.
CE/bazedoxifene has not been studied in patients with impaired liver function(see sections 4.2 and 5.2) or history of cholestatic jaundice.

Pri bolnikih z okvarjenim delovanjem jeter klinične študije niso bile izvedene, vendar zaradi načina uporabe in zelo nizke sistemske absorpcije prilagajanje odmerkov ni potrebno.
Clinical studies have not been performed in patients with impaired hepatic function, however due to its method of administration and very low systemic absorption, no dosage adjustment is required.

Okvarjeno delovanje jeter Pri bolnikih z blago okvarjenim delovanjem jeter(Child- Pugh razred A) niso opazili kakih pomembnih sprememb v farmakokinetiki.
Hepatic impairment In patients with mildly impaired liver function(Child-Pugh class A) no relevant changes in the pharmacokinetics have been observed.

Pri bolnikih z okvarjenim delovanjem jeter je priporočljivo skrbno spremljanje najmanjše koncentracije sirolimusa v polni krvi(glejte Terapevtsko spremljanje koncentracije zdravila in prilagajanje odmerka).
It is recommended that sirolimus whole blood trough levels be closely monitored in patients with impaired hepatic function(see Therapeutic monitoring of the medicinal product and dose adjustment).

Približno 50% bolnikov z okvarjenim delovanjem jeter in hepatomegalija po prepoznavanju oddaljenih metastaz živi 6-9 mesecev.
About 50% of patients with impaired liver function and hepatomegaly live 6-9 months after identifying distant metastases.

Pri bolnikih z blago do zmerno okvarjenim delovanjem jeter je treba biti previden in nadzorovati je treba delovanje jeter..
In patients with mild to moderate hepatic impairment, caution should be exercised and monitoring of liver function should be performed.